{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"description":"Long term safety and tolerability of IMO-8400 in patients with Waldenstrom's Macroglobulinemia","groups":[{"description":"Subcutaneous injection of IMO-8400 0.6 mg/kg/wk or 1.2 mg/kg twice weekly per Protocol 8400-401","id":"OG000","title":"IMO-8400 0.6 mg/kg/wk or 1.2 mg/kg 2xwk"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety population","reportingStatus":"POSTED","timeFrame":"During receipt of study treatment on the trial.","title":"Number of Participants With Adverse Events","type":"PRIMARY","unitOfMeasure":"Participants"}